CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 117 enrolled
Drug / intervention
SpO2 Sensor application & blood drawdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03383757
NCT03383757N/ACompleted

U-TruSignal SpO2 Testing in Neonates

GE Healthcare·interventional·Posted Dec 26, 2017·Updated Dec 4, 2020

In Brief

A clinical study evaluating SpO2 Sensor application & blood draw for Pulse Oximetry. Completed, enrolled 117 participants across 2 sites in 2 countries.

Detailed Summary

The purpose of the study is to demonstrate proper function of the U-TruSignal device via clinical performance testing in a neonatal human subject population under standard clinical conditions. A study with human subjects will provide the needed clinical evidence for assessing the accuracy of the pulse oximeter as recommended by the FDA Guidance Document (Pulse Oximeters - Premarket Notification Submissions \[50(k)s\]: Guidance for Industry and Food and Drug Administration Staff.)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulse Oximetry
CountriesFinland, India
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedDec 26, 2017
Enrollment StartSep 14, 2017
Primary CompletionNov 1, 2019
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 8.5 years ago

Interventions

SpO2 Sensor application & blood drawdevice

At the start of the procedure, one to two commercial sensors shall be applied to the subject. Readings will be allowed to stabilize. After at least 10 minutes of data collection, arterial blood will be collected and analyzed blood per hospital's standard procedure. Data collection will continue post blood draw for two minutes.